Tango Therapeutics director sells 3,333 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tango Therapeutics, Inc. director John B. Ketchum sold 3,333 shares of common stock on November 17, 2026, at a weighted-average sale price of $24.08 per share; individual sale prices ranged from $24.08 to $25.0799. The sale was made under a Rule 10b5-1 trading plan adopted August 18, 2026. Shares reported following the sale totaled 21,604, including 4,000 unvested RSUs.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 3,333 | $24.08 | $80K |
Footnotes (3)
- F1. The transaction was effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2026.
- F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $24.08 to $25.0799 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. The amount reported in Column 5 includes Restricted Stock Units ("RSUs"), including 4,000 unvested RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Restricted Stock Units (RSUs) financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.